Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $74,202.50 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,350 shares of the business’s stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $22.15, for a total value of $74,202.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.89, for a total transaction of $130,672.50.
• On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $28.56, for a total value of $178,500.00.
• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $24,420.00.
• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $34,937.70.

Enliven Therapeutics Stock Up 0.5 %

Enliven Therapeutics stock traded up $0.11 during trading hours on Tuesday, hitting $22.50. The stock had a trading volume of 90,373 shares, compared to its average volume of 252,244. Enliven Therapeutics, Inc. has a fifty-two week low of $10.90 and a fifty-two week high of $30.03. The company has a market cap of $1.10 billion, a PE ratio of -11.84 and a beta of 1.02. The company has a 50-day moving average of $25.45 and a two-hundred day moving average of $24.29.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC raised its position in Enliven Therapeutics by 295.8% in the third quarter. Barclays PLC now owns 56,217 shares of the company’s stock worth $1,435,000 after purchasing an additional 42,012 shares in the last quarter. Ally Bridge Group NY LLC bought a new position in shares of Enliven Therapeutics during the 3rd quarter worth approximately $5,998,000. Patient Square Capital LP bought a new position in shares of Enliven Therapeutics during the 3rd quarter worth approximately $2,313,000. First Turn Management LLC boosted its stake in Enliven Therapeutics by 29.5% in the 3rd quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock valued at $13,666,000 after buying an additional 121,849 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Enliven Therapeutics by 9.9% in the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock valued at $19,164,000 after acquiring an additional 67,813 shares during the period. 95.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

ELVN has been the subject of a number of recent analyst reports. Robert W. Baird upped their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, November 15th. BTIG Research assumed coverage on Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Enliven Therapeutics currently has an average rating of “Buy” and a consensus price target of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.